Comparing eXoZymes (EXOZ) & Its Competitors

eXoZymes (NASDAQ:EXOZ) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare eXoZymes to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for eXoZymes and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1	0	0	0	1.00
eXoZymes Competitors	5916	12229	37690	1173	2.60

As a group, “MED – BIOMED/GENE” companies have a potential upside of 49.70%. Given eXoZymes’ peers stronger consensus rating and higher possible upside, analysts plainly believe eXoZymes has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares eXoZymes and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
eXoZymes	$70,000.00	-$5.86 million	-19.88
eXoZymes Competitors	$965.54 million	-$45.66 million	12.83

eXoZymes’ peers have higher revenue, but lower earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares eXoZymes and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-104.58%	-79.55%
eXoZymes Competitors	-1,425.99%	-589.65%	-28.81%

Institutional and Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

eXoZymes peers beat eXoZymes on 8 of the 12 factors compared.

eXoZymes Company Profile

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.